# Blenrep (belantamab mafodotin-blmf) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/belantamab-mafodotin-blmf

> Blenrep (belantamab mafodotin-blmf), sponsored by GSK plc (GSK), received a complete response letter from the FDA; the decision is dated October 23, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Blenrep (belantamab mafodotin-blmf) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### July 17, 2025: FDA advisory committee meeting

- Status: completed, negative. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss BLA 761440, belantamab mafodotin submitted by GlaxoSmithKline LLC, for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior line of therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide." https://www.fda.gov/advisory-committees/july-17-2025-meeting-oncologic-drugs-advisory-committee-07172025
- FDA advisory committee calendar: "VOTE: Is the overall benefit-risk of belantamab mafodotin in combination with bortezomib and dexamethasone favorable at the proposed dosage in the proposed patient population? Vote Result: Yes: 3 No: 5 Abstain: 0" https://www.fda.gov/media/188764/download
- FDA advisory committee calendar: "VOTE: Is the overall benefit-risk of belantamab mafodotin in combination with pomalidomide and dexamethasone favorable at the proposed dosage in the proposed patient population? Vote Result: Yes: 1 No: 7 Abstain: 0" https://www.fda.gov/media/188764/download

### October 23, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761440 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20251023, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BLENREP (BELANTAMAB MAFODOTIN-BLMF)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761440%22

### October 23, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed the review of BLA 761440/Original 2, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761440_20251023.pdf%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/belantamab-mafodotin-blmf.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Blenrep (belantamab mafodotin-blmf) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/belantamab-mafodotin-blmf

```bibtex
@misc{secapidev_pdufa_belantamab_mafodotin_blmf_20261116,
  title        = {Blenrep (belantamab mafodotin-blmf) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/belantamab-mafodotin-blmf}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_belantamab_mafodotin_blmf_20261116","title":"Blenrep (belantamab mafodotin-blmf) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/belantamab-mafodotin-blmf","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
